 There is no current evidence supporting the use of carglumic acid for the chronic management of patients with OA. The investigators are proposing a randomized multicentre prospective clinical trial to evaluate long-term effects of the use of Carbaglu 50mgkgday combined with standard chronic therapy in patients with PA and MMA compared to standard chronic therapy alone. 